Bristol-Myers Squibb Company

06/11/2021 | Press release | Distributed by Public on 06/11/2021 01:04

Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl®(luspatercept-aamt) in Adults with Non-Transfusion Dependent(NTD)Beta Thalassemia